To the Editor:

In chronic obstructive pulmonary disease (COPD), exacerbation history is the strongest predictor of future exacerbation risk \[[@C1], [@C2]\]. Large cohort studies have shown that patients with one exacerbation in the previous year have an approximately two-fold increased future exacerbation risk compared to patients with no exacerbations, the risk increasing to five-fold in those with two or more exacerbations \[[@C1], [@C2]\]. Most clinical trials of pharmacological treatments designed to prevent exacerbations have therefore used the inclusion criterion of at least one exacerbation in the previous year, with a minority requiring at least two exacerbations \[[@C3]--[@C6]\].

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report advocates the "ABCD" classification after initial diagnosis to identify patients at high risk of exacerbations, using the criteria of two or more exacerbations requiring systemic corticosteroids and/or antibiotics ("moderate exacerbations") or a single exacerbation leading to hospitalisation ("severe exacerbation") in the previous year \[[@C7]\]. The 2019 GOLD update provides treatment algorithms for follow-up therapy, with inhaled corticosteroid (ICS)-containing (double or triple) combinations recommended for patients who continue to have exacerbations \[[@C8]\]. However, a gap in the evidence is whether the addition of ICS provides a clinical benefit in patients who have just one moderate exacerbation in the past year despite receiving maintenance treatment.

A single triple combination inhaler containing an extrafine formulation of the ICS beclometasone dipropionate (BDP), the long-acting β~2~-agonist (LABA) formoterol fumarate (FF) and the long-acting muscarinic antagonist (LAMA) glycopyrronium (G) has been developed to simplify therapy in patients with COPD, whilst ensuring efficient lung delivery of all three molecules. TRILOGY, TRINITY and TRIBUTE were three 52-week studies that evaluated the efficacy and safety of BDP/FF/G compared with BDP/FF (TRILOGY), tiotropium and BDP/FF plus tiotropium (TRINITY), and the fixed-dose combination of indacaterol and glycopyrronium (IND/GLY) (TRIBUTE) \[[@C3]--[@C5]\]. All three studies recruited symptomatic patients (COPD Assessment Test total score ≥10) with a history of at least one moderate-to-severe exacerbation, post-bronchodilator forced expiratory volume in 1 s (FEV~1~) \<50% of predicted and who were receiving maintenance inhaled therapy for at least 2 months prior to entry with long-acting bronchodilator monotherapy or dual combination therapy but not triple therapy; this population therefore allowed an investigation of step-up to triple therapy.

Here we report the results of *post hoc* analyses of the efficacy and safety of extrafine BDP/FF/G in the subgroup of patients with symptomatic COPD, severe or very severe airflow limitation, and a history of one moderate exacerbation despite maintenance therapy; patients with any exacerbation resulting in an emergency department visit or hospitalisation were excluded.

The designs and results of TRILOGY, TRINITY and TRIBUTE have been previously published \[[@C3]--[@C5]\]. Briefly, during the 2-week run-in, all patients received BDP/FF in TRILOGY, tiotropium in TRINITY, and IND/GLY in TRIBUTE. The studies then randomised one group of patients to receive extrafine BDP/FF/G 87/5/9 µg (100/6/10 µg *ex valve*) two puffs twice daily *via* pressurised metered dose inhaler (pMDI). The comparator groups were: TRILOGY, extrafine BDP/FF 87/5 µg (100/6 µg *ex valve*), two puffs twice daily *via* pMDI; TRINITY, tiotropium 18 µg once daily *via* single-dose dry powder inhaler (SDDPI), or extrafine BDP/FF 87/5 µg two puffs twice daily *via* pMDI plus tiotropium 18 µg once daily *via* SDDPI; TRIBUTE, IND/GLY 85/43 µg (110/50 µg per capsule) one puff once daily *via* SDDPI. The studies are registered in ClinicalTrials.gov: TRILOGY, NCT01917331; TRINITY, NCT01911364; TRIBUTE, NCT02579850. Pre-dose morning FEV~1~ and St George\'s Respiratory Questionnaire (SGRQ) were assessed at baseline and weeks 4, 12, 26, 40 and 52, with moderate-to-severe exacerbations assessed over the study duration. The number of moderate/severe COPD exacerbations was analysed using a negative binomial model. FEV~1~ and SGRQ mean changes from baseline were evaluated using a linear mixed model for repeated measures, with a logistic regression model used to analyse SGRQ responders. The statistical models used were consistent with the overall study analyses \[[@C3]--[@C5]\]. The number needed to treat (NNT) was calculated for exacerbations: both event-based (the NNT for 1 year with BDP/FF/G rather than the comparator to prevent one moderate/severe COPD exacerbation) and person-based (the NNT for 1 year with BDP/FF/G rather than the comparator to prevent one patient from experiencing any exacerbation).

The subgroup of patients with one moderate exacerbation in the previous 12 months represented 55.1%, 49.2% and 63.3% of the overall population in TRILOGY, TRINITY and TRIBUTE, respectively. There were no substantial differences between groups in baseline demographics or disease characteristics, either within or among the three studies. The majority of patients (82.0% overall) included in the analyses had severe airflow limitation (FEV~1~ 30--50% predicted).

The effect of BDP/FF/G on moderate-to-severe exacerbations was consistent across the three studies, with a 23% reduction *versus* BDP/FF (TRILOGY), a 22% reduction *versus* tiotropium (TRINITY), and a 23% reduction *versus* IND/GLY (TRIBUTE) ([figure 1a](#F1){ref-type="fig"}). The event-based NNTs were nine, 10 and nine for BDP/FF/G *versus* BDP/FF, tiotropium and IND/GLY, respectively, with person-based NNTs of 16, 87 and 26, respectively. BDP/FF/G provided significantly greater improvements in SGRQ total score *versus* BDP/FF and IND/GLY overall (*i.e.* averaged from all study visits) and at week 52, and *versus* tiotropium overall ([figure 1b](#F1){ref-type="fig"}). Patients receiving BDP/FF/G were significantly more likely to be SGRQ responders at week 52 than those receiving BDP/FF or IND/GLY ([figure 1b](#F1){ref-type="fig"}). In TRINITY, the proportion of SGRQ responders to BDP/FF/G was higher compared to tiotropium, but the odds ratio was not statistically significant. BDP/FF/G also provided significantly greater improvements in lung function (pre-dose morning FEV~1~) *versus* BDP/FF and tiotropium overall and at week 52 and *versus* IND/GLY overall ([figure 1b](#F1){ref-type="fig"}).

![a) Adjusted annual rate of moderate-to-severe chronic obstructive pulmonary disease exacerbations (intention-to-treat population). b) Between-treatment differences in St George\'s Respiratory Questionnaire (SGRQ) total score and forced expiratory volume in 1 s (FEV~1~) at week 52 and overall, and SGRQ responders at week 52 (intention-to-treat population). Data are adjusted mean differences or odds ratios with 95% confidence intervals and p-values. SGRQ responders are patients with a decrease from baseline in SGRQ total score of at least 4 units. BDP: beclometasone dipropionate; FF: formoterol fumarate; G: glycopyrronium; IND/GLY: indacaterol/glycopyrronium.](ERJ-00235-2019.01){#F1}

Overall, the incidence of adverse events was similar for BDP/FF/G compared to the other treatments (50.8--61.4% for BDP/FF/G, 50.9% for BDP/FF, 55.8% for tiotropium, 57.0% for BDP/FF plus tiotropium, and 68.5% for IND/GLY). The incidence of pneumonia was low, and apart from tiotropium monotherapy in TRINITY, was similar across treatment groups including IND/GLY in TRIBUTE (2.3--3.2% for BDP/FF/G, 2.1% for BDP/FF, 0.8% for tiotropium, 1.5% for BDP/FF plus tiotropium, and 3.2% for IND/GLY).

The results of these *post hoc* analyses in patients with symptomatic COPD, severe or very severe airflow limitation, and who had one moderate exacerbation in the previous year despite receiving regular inhaled maintenance therapy with single long-acting bronchodilator or dual combination therapy prior to entering the study, showed that inhaled triple therapy with extrafine BDP/FF/G provided clinical benefits compared with LAMA, ICS/LABA and LABA/LAMA. Of note, these effects were observed on the important clinical end-points of exacerbations and health-related quality of life, along with FEV~1~. These analyses therefore provide guidance on therapy for this group of patients often considered not at high risk of future exacerbations. GOLD does not define a level of exacerbations at which treatment escalation should occur; our results provide evidence to support the use of triple therapy even at the threshold level of only one moderate exacerbation, although we acknowledge that these are mean data, and there is variation between individuals.

The perception that the GOLD ABCD grouping has inadvertently created is that only patients with at least two exacerbations or one exacerbation resulting in hospitalisation require pharmacological treatments to prevent future exacerbations. This overlooks the substantial heterogeneity within COPD. Our results emphasise the importance of considering both the clinical characteristics and current therapy when selecting alternative treatment options for patients with COPD.
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